GPP Policy Asia Tenggara

A Conference on GPP Policy and Plans for the
South East Asia Region
Bangkok, Thailand
June 27th – 29th, 2007
TABLE OF CONTENTS
Executive Summary ……………………………………………...… iv
1. Background ………………………………………………..…...… 1
1.1) General Objectives ………………………………...……….……... 1
1.2) Specific Objectives ………………………………………...….….. 1
1.3) Expected Outcomes ……………………………………………….. 2
2. Actual Outcomes ……………………………………….……………….. 2
3. Session Summary ……………………………………………...…. 3

3.1) Inaugural Session ……………………………………………….… 3
3.2) Reports on GPP Status in SEA …………………………………… 4
3.3) Discussion on Proposed Regional GPP Policy …………………… 6
3.4) Experience Sharing on GPP Development & Implementation …… 6
3.4.1) Separation of Prescribing & Dispensing………………….. 6
3.4.2) National Strategic Plans & Plan of Actions …..….……… 8
3.5) Measures Taken: Accreditation of Pharmacies ............................. 10
3.5.1) Australia’s Experience……………………………………… 10
3.5.2) India’s Experience………………………..…………….…… 11
3.5.3) Thailand’s Experience…………………..……………..…… 11
3.6) Group Discussion on Country’s Policy & Plans ………………… 12
3.7) Supporting Organization’s Role & Responsibilities in GPP ……. 15
3.8) Support, Collaboration and Implementation Mechanism ……….. 17
3.9) GPP Strengthening Plans ………………………………………... 25
3.10) Open Discussion ……………………………………………...…. 26
3.11) Field Visits …………………………………………………….… 26
4. Conclusion & Recommendation …………………………………27
ii
Annexes
1. Self-Assessment Questionnaire …………………………..…….. 28

2. Conference Programme …………………………………..…….. 61
3. Bangkok Declaration on Good Pharmacy Practice
In Community Pharmacy Settings ………………………….….. 65
4. Key Participant Information ……………………………...……. 69
iii
Executive Summary
More than 70 pharmacists from 14 countries came to meet, share experience, discuss and
brainstorm on GPP policy and plans for the South East Asia Region. This conference was
technically and financially supported by international organizations (WHO and FIP), regional
pharmaceutical fora (SEARPharm Forum and WPPF) and countries from South East Asia and
Western Pacific Regions.
Several good things were achieved during the conference. Besides sharing of knowledge and
experiences, networking, collaboration and commitment on GPP development and
implementation among participants and delegates from supporting organizations were
obvious. They all helped identify ways to address current challenges and issues on GPP
development and implementation.
Two concrete outcomes aiming to promote GPP development and implementation were
derived from the conference. First, 6 strategies and 61 tactics were achieved and ready to be
adopted by interested participating countries. Second, “Bangkok Declaration on Good
Pharmacy Practice in the Community Pharmacy Settings in the South East Asia Region” was
adopted to show support and commitment in promoting GPP within the region.
It is obvious that actual GPP development and implementation within individual participating
countries depend on the dynamics and commitment of all local stakeholders. Therefore, it is
highly recommended that constant stimulation via follow-up or experience sharing sessions
among participants and supporting organizations be held on a regular basis. This can promote
GPP development and implementation within the region to a certain degree.
iv
1. Background
Good Pharmacy Practice (GPP) in community pharmacy settings can promote health and
well-being of the population if it exists and is observed. Countries in South East Asia Region
are moving towards GPP, but at their own pace and direction. To expedite such movement,
each country’s initiation and participation, experience sharing, and advice as well as support
from resource countries and/or organizations are essential. This calls for a conference on
GPP policy and plans, both in regional and country perspectives. The dynamics within the
conference can certainly promote a good understanding, a unified direction and collaborations
among all parties involved.
As a result, the Pharmaceutical Association of Thailand under Royal Patronage in

collaboration with the Thai Food and Drug Administration held a first Regional Conference
on GPP Policy and Plans for the South East Asia Region at Royal River Hotel, Bangkok,
Thailand during June 27 – 29, 2007. The Conference was supported by SEARPharm Forum,
Western Pacific Pharmaceutical Forum (WPPF), FIP and WHO.
The 13 countries to be originally focused in this conference are as follows:

• SEARPharm members
o Bangladesh { Bhutan { DPR Korea
o India { Indonesia { Maldives
o Myanmar { Nepal { Sri Lanka
o Thailand
• SEARPharm non-members
o Cambodia { Laos { Vietnam
As GPP status of each targeted country is in different stages. Two types of objectives are
illustrated as follows:
1.1 General Objectives
To increase awareness, acceptance, desire and actions related to GPP development and
implementation within each participating country at his/her own appropriate pace
1.2 Specific Objectives
Specific objectives expected from the conference are:

• GPP status of all 13 participating countries are presented
• GPP regional policy is discussed, concluded and endorsed
1
• At least, country policy & plans from five top priority countries are formulated. Those
countries are: India, Indonesia, Nepal, Sri Lanka and Thailand
• Collaborations among parties involved are identified
1.3 Expected Outcomes
It was expected that more effective and efficient country plans would be achieved from the
conference. Then, the plans would be discussed, fine tuned and approved with local
stakeholders within each participating country. In addition, regional GPP policy and plans
would be finalized and approved. The outcomes of the Conference would be used as
presentation materials for the 67th FIP Annual Congress in Beijing, China during September
1-6. This would invite more comments, suggestions and/or supports; therefore, the
strengthening of GPP activities in the regions would occur without any further delays.
2. Actual Outcomes
The conference was attended by more than 70 pharmacists from 14 countries, comprising of
public, private, academia, council and association sectors. Several resource persons were
from the four supporting organizations, i.e., SEARPharm Forum, Western Pacific
Pharmaceutical Forum (WPPF), FIP and WHO.
Countries participating in the conference were:

{ Bhutan { India { Indonesia { Maldives { Nepal
{ Sri Lanka { Thailand { Taiwan { Japan { Cambodia
{ Laos { Mongolia { Vietnam { Australia
The conference was accomplished as originally planned. However, a decision was

collectively made during the conference. Focusing on individual country plans to formulate
more effective and efficient ones was changed to a brainstorming session regarding GPP
plans on a team basis via basket exercises. Therefore, actual outcomes became threefold: a)
strategies and tactics to effectively and efficiently develop and implement GPP, b) networks
of countries with common strategies and tactics, and c) GPP regional policy, entitled
“Bangkok Declaration on Good Pharmacy Practice in Community Pharmacy Settings”
Finally, it was expected that GPP development and implementation process in each
participating country could be accelerated. This was because necessary strategies, tactics and
collaboration among countries with common interests within the regions and with supporting
organizations, i.e., SEARPharm Forum, WPPF, FIP and WHO were already identified.
2
3. Session Summary
3.1 Inaugural Session
Key persons delivered their remarks/address during the opening session included:
• Welcome remark by Dr. P.T. Jayawickramarajah, WHO Representative to

Thailand
Dr. P.T. Jayawickramarajah, WHO Representative to Thailand delivered his welcome remark
by expressing his pleasure to be associated with professions thinking about GPP. He then
emphasized an importance of practicing GPP in twofold: a) practicing GPP not only helped
solving irrational drug use, the weakest part of an “Essential Medicines List (EML)”, but also
fulfilled a requirement of being professionalism. Relationships between the population and
health care providers could become more of a social contract than a somewhat business one
and b) practicing GPP could promote pharmacists in South East Asia Region to evolve, i.e.,
from a perceived image of “an occupation supplying medicine” to “a health care profession
providing pharmaceutical care” and from “earning profit from medicine” to “charging fee for
service”. Dr. P.T. Jayawickramarajah closed his remark by confirming that GPP was the way
to go for professional pharmacists.
• Welcome remark by Dr. Peter J. Kielgast, Chairman, FIP Foundation for

Education and Research
Dr. Peter J. Kielgast, Chairman, FIP Foundation for Education and Research, conveyed his
greetings and emphasized three important issues as follows: a) an importance of GPP on
public health and the health care system, b) a successful GPP implementation process through
an integrative approach, i.e., not only pharmacists, but also back-ups were necessary, e.g.,
legislations, health strategic plans and educational system and c) FIP’s roles on GPP support
at a national level. After three years of support at a national level, e.g. to Thailand, FIP’s
support would come to an end; however, FIP would determine its path forward within the
coming months. In addition, Dr. Peter J. Kielgast also expressed his sincere gratitude to
Danish, Swedish and especially Taiwan members for their financial support and commitment
to FIP. He concluded by wishing all participants receive useful information and ideas on how
to develop and implement GPP in a complete process.
3
• Welcome remark by Prof. Dr. Pavich Tongroach, President, the
Pharmacy Council
Prof. Dr. Pavich Tongroach, President, The Pharmacy Council, welcomed everyone to
Bangkok and to the conference. He familiarized the audience with the role of Pharmacy
Council, i.e., a legal authority responsible for regulating and promoting a pharmacy
profession in Thailand. From the Council’s point of view, a concept of GPP was seen as a
strategic move to maintain high standard of professional conduct. Then, he outlined a joint
effort with other professional bodies in Thailand to promote GPP in all pharmacy areas.
Examples of success cases included: a) GPP in hospital pharmacy sector became part of a
nation-wide hospital accreditation scheme and b) GPP in community pharmacy sector became
a guideline for an accreditation of community pharmacies. Prof. Dr. Pavich Tongroach also
pointed out that an accreditation of pharmacies had moved very slowly, and the Council had
been working on improving the situation. Finally, he congratulated the organizer, thanked
FIP and WHO for their support and hoped that the conference could bring some immediate
solutions for an implementation of GPP in individual participating countries.
• Inaugural address by Dr. Siriwat Tiptaradol, Secretary – General,

Thailand Food and Drug Administration
Dr. Siriwat Tiptaradol, Secretary – General of Thailand Food and Drug Administration
welcomed participating organizations and individuals to Thailand and the conference. He
then familiarized the floor with four important issues as follows: a) Government’s attempt to
promote effective and efficient access to quality health services in Thailand through the
2002’s National Health Insurance Act, b) role of the Thai Pharmacy Council in promoting
patient safety through an accreditation of pharmacies with Thai GPP as accreditation criteria,
also in 2002, c) his gratitude on delegates from WHO-SEARO and FIP for their support on
GPP through SEARPharm Forum and d) his expectation on the outcomes of this conference
on GPP in South East Asia Region. Finally, Dr. Siriwat Tiptaradol concluded his address by
declaring open the conference and wishing everybody all the success.
3.2 Reports on GPP Status in SEA
Ms. Chongmas Nitisingkarin, Secretary General of Community Pharmacy Association

(Thailand) presented major findings on GPP status in South East Asia Region. The status
covered was that on: a) attitude towards community pharmacists, b) information on
community pharmacists, c) continuing education system, for pharmacists, d) FIP/WHO
standards for community pharmacies, and e) Legislation and National Drug Policy. Those
findings were uncovered from the self-assessment questionnaire developed form FIP’s GPP
4
implementation guidelines and surveyed between April and May, 2007.
Within six out of ten countries in South East Asia (SEA) Region, i.e., Bhutan, India, Maldives,
Nepal, Sri Lanka and Thailand, attitude towards community pharmacists varied between low
and moderate levels. Population had low awareness on the role and responsibilities of
community pharmacists, resulting in low requests for community pharmacist’s services at the
pharmacy. Likewise, community pharmacists’ attitude on their own professional role was
also low; however, their attitude on GPP was somewhat better, i.e., at a moderate level. In
terms of other health professionals, their attitude on community pharmacists was at a
moderate level, resulting in an average professional relationship with community pharmacists.
Similarly, pharmacy owners’ attitude on community pharmacists was also at a moderate level.
Regarding information on community pharmacists in community pharmacies, survey

revealed an insufficient number of qualified pharmacists in the pharmacies. The ratio
between community pharmacists and population served varied from 1:3,500 to 1:520,000. In
some countries, pharmacy technicians or trained persons were qualified to work in the
pharmacies. In addition, most pharmacies didn’t employ full-time pharmacists.
Continuing education system for pharmacists existed only one out of six countries
responded. However, the available system was on a voluntary basis.
Based on FIP/WHO standards for community pharmacies, information on premises,

dispensing processes, containers & labeling, patient medical records, health information &
patient counseling was surveyed. It is obvious that most countries responded had a separate
service area, a refrigerator and moderately clean premises. In terms of dispensing processes,
prescription checking on adverse drug reactions and double checking routines prior to
dispensing of medicines was mostly not accomplished. However, correct and clear
instructions were moderately provided. Surprisingly, original packages were containers
mostly used while labeling performed was lower than the minimum labeling requirements.
Doses and frequencies were among those mostly labeled. Patient medical records intended to
facilitate patient care and audit trials, were mostly not accomplished, neither was providing
health information and patient counseling.
In terms of Legislation and National Drug Policy, almost all countries had GPP policy in
place; however, only one country had it implemented, but on a voluntary basis. In addition,
the survey revealed that all countries responded had established their own National Drug List.
5
In conclusion, within the six SEA countries responded, problems identified were:
• Population attitude towards community pharmacists and community pharmacists’
attitude on their own professional role
• An insufficient number of community pharmacists in community pharmacies
• A continuing education system for pharmacists
• Standards for community pharmacies:
o Dispensing processes - prescription checking, mostly not accomplished
o Labeling - lower than the minimum labeling requirements
o Patient medical records - mostly not accomplished.
o Health information and patient counseling - mostly not provided.
• GPP policy – not fully implemented
3.3 Discussion on Proposed Regional GPP Policy
Dr. Songsak Srianujata, Executive Committee Member of the SEARPharm Forum,

familiarized the proposed Regional GPP Policy to the audience. Then, he emphasized on two
important issues: a) GPP in community pharmacy could be one of the major steps for
community pharmacists to be recognized as health service providers and b) successful GPP
implementation needed collaboration among all stakeholders.
Finally, Dr. Songsak Srianujata concluded his presentation by requesting the audience to
think carefully about the proposed policy before finalizing it at the end of the conference.
3.4 Experience Sharing on GPP Development & Implementation
Dr. Th (Dick) FJ Tromp chaired the experience sharing session, consisting of three parts as
follows:
• GPP development and implementation in relation to “Separation of Prescribing and
Dispensing”, presented by delegates from Japan and Taiwan
• GPP development and implementation, “National Strategic Plan and Plan of Actions”,
presented by delegates from Mongolia, Vietnam, Cambodia and Lao PDR
• Measures taken for GPP development and implementation: Accreditation of
Pharmacies, presented by delegates from Australia, India and Thailand
3.4.1 Separation of Prescribing & Dispensing
Speakers from Japan and Taiwan shared their experience on the separation of prescribing
and dispensing as follows:
6
o Japan’s Experience
Mr. Daisuke Kobayashi, Japan Pharmaceutical Association (JPA) shared experiences on

two important points: a) history of the separation of medical professionals from
dispensing, i.e., Bungyo (in Japanese) and b) patient-centered initiatives by the
Government, JPA and individual pharmacies to promote Bungyo.
Bungyo started in 1889; however, it was not successful due to an insufficient number of
qualified pharmacies and an exceptional permission to dispense, given to physicians by
the Medical Act.
Equipped with an increasing cost of health care under the Health Insurance System and
policies to provide its population with an efficient and high-quality health care, the
Government decided to make Bungyo function with high quality. Examples included an
offering of financial incentives to both physicians and pharmacists (1973) and four
revisions of the dispensing fees in 1974, 1984, 1997 and 2000.
In terms of JPA and individual pharmacies’ initiatives, several projects were initiated to
encourage pharmacists to provide more appropriate drug information and pharmaceutical
consultation based on medical records and to take thorough measures to prevent
dispensing errors. Examples included: a) an improvement of infrastructure (e.g.,
pharmacy distribution, drug stock centers and drug information & training centers), b)
medical history management service, c) supply of drug information, d) spread & use of
the drug notebook for individual patients and e) an expansion of relevant pharmacist’s
roles and education.
Unfortunately, due to time constraint, Mr. Daisuke Kobayashi could not cover future
vision and some public campaigns in Japan.
o Taiwan’s Experience
Ms. Shawn Hsiang-Yin Chen, Chairman, International Affairs Committee, Taiwan

Society of Health-System Pharmacists shared experiences in threefold: a) a history of the
separation, b) strategies for the implementation and c) an analysis of the driving forces.
The Separation of Prescribing and Dispensing Policy (Separation policy) was

implemented in 1997, two years after National Health Insurance Act had allowed
qualified community pharmacies to contract with the Bureau of National Health Insurance
(BNHI).
7
The implementation strategies used were: a) a district-to-district and a phase-in step, b)
two tiers strategy, and c) a re-design strategy. It took them several years to complete a
policy implementation in Taipei and Kaochung (1997), West of Taiwan (1998), East of
Taiwan (1999) and the islands (2002). At that time, community pharmacies did not gain
enough public trust, therefore, a two tiers strategy dealt only with clinics. Physicians in
clinics were encouraged to release prescriptions to patients, and clinics were allowed to
employ in-house pharmacists (Phase I).
In 1995, 38 prescriptions were released to BNHI contracted pharmacies, around 2

millions in 1997 and around 70 millions in 2005. Although they were quite successful, a
re-design strategy was initiated (Phase II). Examples included a re-design of a) the NHI
system to facilitate hospital’s release of prescriptions, b) restrictions to avoid front door
pharmacy and house-in pharmacists in clinics and c) the system to accommodate quality
generic substitution.
Ms. Shawn Hsiang-Yin Chen also pointed out three main driving forces for the Separation
Policy as follows: a) relevant legislation, b) cooperation between the Government and
Pharmacist Associations including local health authority and c) public education. These
forces ensured: a) a release of prescriptions, b) quality of community pharmacies,
pharmacists and pharmaceutical services, c) a network between hospitals and pharmacies
and d) public awareness on their rights for services available at the pharmacies.
Ms. Shawn Hsiang-Yin Chen concluded by stressing that incorporating the concept of
GPP into the execution of the separation policy would demonstrate the value of
pharmacists.
3.4.2 National Strategic Plan & Plan of Actions
Speakers from Mongolia, Vietnam, Cambodia and Lao PDR shared their National
strategic plan and plan of actions as follows:
o Mongolia’s Experience
After introducing to the audience on her country, community pharmacy infrastructure and
services rendered, Ms. P. Tsetsgee from Pharmaceuticals and Medical Devices
Department, Ministry of Health, presented Mongolia’s GPP strategic plan. Several
weaknesses and threats from SWOT analysis were focused in the plan. Examples
included legislation implementation, pharmacist’s competence, pharmacy accreditation,
8
prescription behavior and quality control. Within each objective of the plan, several plans
of action were presented. For example, plans to improve implementation of legislation on
GPP included: a) renewing national standard for pharmacies on general principles, b)
developing and printing reference materials for GPP, c) training the trainers on GPP and
d) conducting training on the use of computers in pharmacies. At the end, Ms. P. Tsetsgee
concluded that pharmacy service standards would be raised up to a level that promotion of
health and well-being of the population could be realized.
o Vietnam’s Experience
Mr. Chu Dang Trung, Vice Head of Division of Pharmaceutical, Legislation & Policy,
Drug Administration of Vietnam was a speaker of this session. He presented that in
response to the National Drug Policy, dated 20/6/1996, total quality management (TQM)
in Pharmaceutical industry was initiated, and it dealt with quality assurance of both
pharmaceutical products and clinical therapy.
In terms of GPP in Vietnam, it started in 2007 and composed of 3 chapters, i.e., general
requirements, criteria (on staff, facilities and major activities within the pharmacies) and
implementation guidance, based on WHO guidelines. Furthermore, incentives to practice
GPP and implementation roadmap were already established. GPP implementation
deadlines were set for different locations of pharmacies, e.g., pharmacies in inner big
provinces (Hanoi, HCM, Can Tho & Da Nang), from 01/07/2007 and those in inner other
provinces, from 01/01/2009. In conclusion, from 01/01/2011, GPP would be obligatory for
all pharmacies. Those not complying had to be closed down. Mr. Chu Dang Trung also
stated that weaknesses in part of legislation, regulatory authorities and the
enterprises/pharmacies were the main obstacles to implement GPP in Vietnam.
o Cambodia’s Experience
Dr. Chroeng Sokhan, Deputy – Director, Department of Drugs and Food, Ministry of
Health, mentioned that after 1996, a lot of legislation and regulation had been issued and
implemented, and GPP was one of them. Since GPP guideline was recently set up and
ready to be issued, not a lot of experience could be shared. However, he would share
experience on establishing Cambodia pharmaceutical strategic plan instead.
Based on the information from SWOT analysis, Cambodia strategic plan focused on six
key areas, i.e., health service delivery, behavioral change, quality improvement, human
resources development, financing and institutional development.
9
Dr. Chroeng Sokhan also presented both strategies and expected outcomes of each key
area of the strategic plan. For example, the expected outcome of the strategy on quality
improvement, i.e., “strengthen the implementation of drug policies, laws and regulations
for public safety through setting quality standards, capacity building, supervision and
enforcement” was “health workers and consumers understand and comply with
strengthened drug law and regulations which reflect registration quality, management and
control requirements for all drugs and medical devices”. Upon pursuing the plan, it was
ultimately expected that the health system and the use of drugs would become more
efficient and effective.
o Lao PDR’s Experience
Dr. Sivong Sengaloundeth, Head of Administration Division, Food and Drug Department,
Ministry of Health, stated that to ensure GPP in the pharmacies, 10 GPP indicators were
initiated in 1995, two years after an introduction of the National Drug Policy. Those
indicators were: 1) conditions of premises, space and order in the pharmacy, 2) banned
drug, not available, 3) availability of essential drugs with generic name, 4) drug quality
and expiry date, 5) correct drug purchase bill only; 6) dispensing practice, 7) selling
behavior of malaria and diarrhea drugs, 8) selling antibiotics with prescriptions, 9)
availability of essential materials for good dispensing practice (GDP) and 10) presence of
professional staff. Then, Dr. Sivong Sengaloundeth briefly explained those ten indicators.
3.5 Measures Taken: Accreditation of Pharmacies
Speakers from Australia, India and Thailand shared their experience on an accreditation of
pharmacies as follows:
3.5.1 Australia’s Experience
Mr. John Ware, President of the Western Pacific Pharmaceutical Forum (WPPF) shared
Australian experience regarding an accreditation of pharmacies. In Australia, a quality care
program applied not only to pharmacists, but also to the pharmacy and all staff in the
pharmacy.
In addition, Mr. John Ware pointed out five prerequisites for successful GPP development
and implementation. Those requirements were: a) strong government legislation, b)
education based on standards of competence at entry level, c) ongoing professional
development, d) medicine and pharmacy legislations to protect the public and e) legislation
encouraging professional practice. He also emphasized that the pharmacy
10
associations/societies must be involved in the development and acceptance of professional
practice standards which should also be in line with GPP standards recommended by FIP and
WHO.
After walking through examples of good dispensing guideline (GDP) with the audience, Mr.
John Ware concluded his presentation by illustrating that GDP would be GPP only when it
was offered with important information and given in a manner acceptable to the patient’s
level of understanding.
3.5.2 India’s Experience
Mrs. Manjiri Gharat from Indian Pharmaceutical Association - Community Pharmacy

Division (IPA-CPD) shared experience gained from a pilot project (August 2006 – August
2007) on “Accreditation of Pharmacies in India” in two locations, i.e., Goa and Mumbai.
This project was based on a collaboration between IPA-CPD, WHO, India Country Office
and Drugs Controller General of India.
For this project, several GPP tools were developed. Accreditation worksheet, consisted of
criteria and rating information, was used by assessors during the final accreditation period
while accreditation manual showed detailed explanation / illustrations for the implementation
of each criterion.
Those tools were introduced and distributed to participating pharmacies, i.e., around 40 in
Mumbai and 25 in Goa. By the end of June 2007, those pharmacies would finish a 3-month
period of implementing criteria and upgrading their own pharmacies. During that period of
time, the project coordinators and pharmacy students would visit the pharmacies to monitor
progress and to provide advice / help. Although feedback received was both positive and
negative and the final inspection had not been completed yet, IPA had a plan to upscale this
project for the whole country.
Mrs. Manjiri Gharat concluded that with the GPP guideline from WHO, individual countries
could come together, keep together and work together to find their own tools to make an
accreditation of pharmacies effective.
3.5.3 Thailand’s Experience
Dr. Wirat Tongrod, a faculty member of Huachiew Chalermprakiat University, who has been
actively involved in an accreditation of pharmacies in Thailand, assumed a speaker role. He
oriented the audience on three points, i.e., a development of pharmacy accreditation in
11
Thailand, an accreditation process and a key success factor.
An accreditation of pharmacies in Thailand started in 2001 with two aims in mind, i.e., to
improve services provided and to decrease irrational drug use problems. Seven
pharmaceutical bodies, representing pharmacists from community pharmacies, regulatory
bodies and academic institutions, collaborated and worked together for two years to finish the
Thai GPP guideline and to implement it in 2003.
The Thai GPP consisted of five standards as follows: a) Standard I - facility, equipment and
auxiliary services, b) Standard II – quality management c) Standard III – good pharmacy
practice, d) Standard IV – laws, regulations and ethics and e) Standard V – social and
community participation.
In terms of an accreditation process, six steps were elaborated. They were: a) applications
from interested pharmacies, b) self-assessment exercises for self-development purposes, c)
appointments with surveyors for assessment visits, d) surveyors’ visits, e) surveyors’
reporting to the Pharmacy Council and the applied pharmacies and f) surveyors’ meetings for
accreditation decision-making purposes.
Dr. Wirat Tongrod concluded his presentation by emphasizing that stakeholder’s

collaboration was a key success factor for implementing GPP in Thailand. Examples of such
collaboration were: a) the Thai Pharmacy Council initiated and ran the accreditation process,
b) the Community Pharmacy Association of Thailand and the Thai Food and Drug
Administration (FDA) supported and promoted and c) the Pharmaceutical Association of
Thailand under Royal Patronage coordinated between local Thai Pharmaceutical bodies and
international pharmaceutical organizations.
3.6 Group Discussion on Country’s Policy & Plans
Prior to the group discussion session, the audience had an opportunity to participate in the
presentation of Thailand’s GPP policy and plans presented by Ms. Werawan Tangkeo, Vice-
President of Thai Pharmacy Advancement Sub-Committee and Deputy Secretary General,
Thai Food and Drug Administration. This presentation aimed to be a show case for the group
discussion session. As expected, continuous questions and answers were achieved after the
presentation which included the following points:
• Thai GPP policy in community pharmacy settings was established in 2003, by
collaboration among Thai Pharmacy Council, FDA, pharmaceutical associations and
faculties of pharmacy.
• The policy dealt with community pharmacy’s aspects of providing an appropriate, safe
12
and effective use of medicines as well as health promotion and disease prevention
through an accreditation process of community pharmacies. However, it was not quite
successful.
• Four challenges discovered during the self assessment questionnaire accomplished for
this conference included:
o Low public and pharmacist’s awareness on community pharmacist’s role and
responsibilities, resulting in low public request for community pharmacist’s
service
o Quality of community pharmacists
o Quality of community pharmacies and number of those with an accreditation
status
o Relationship between community pharmacists and other health professionals
• As a result, the Thai GPP plan was revised accordingly to emphasize:
o An integration of accredited community pharmacies with the National Health
Insurance System
o Public awareness on professional pharmacy services provided within the
accredited community pharmacies
o Further development of community pharmacist’s potential
Under a guidance of Dr. Songsak Srianujata, Executive Committee Member of the

SEARPharm Forum, participating countries were divided into four groups. Facilitators in
each group guided the discussion through the following topics: a) country GPP status, b)
policy and plans to improve the status c) needs and d) possible sources of support. Then,
facilitators shared the discussion outcomes with the whole audience.
Group # Participating Countries Facilitators
Group I • Mongolia • Dr. Peter J. Kielgast

• India • Mr. Kurt Fonnesbaek Rasmussen
• Maldives
Group II • Vietnam • Dr. Th.F.J. Tromp
• Thailand • Mr. John Ware
• Nepal
Group III • LAO PDR • Dr. Kris Weerasuriya
• Indonesia • Dr. Tom Ahaditomo
• Bhutan
Group IV • Cambodia • Mr. Prafull D. Sheth
• Sri Lanka • Dr. Songsak Srianujata
13
• Group I. -- Mongolia, India and Maldives
Mr. Kurt Fonnesbaek Rasmussen, a group facilitator, presented discussion outcomes of

Mongolia, India and Maldives. GPP status in these three countries was quite similar to that of
most participating countries, i.e., having legislation in place but problems existed in its
implementation. Examples included: a) not perfect collaboration between physicians and
community pharmacists, b) very few prescriptions filled at the pharmacies and c) not many
pharmacists working in the pharmacies. They all needed to address GPP implementation
issues and to be connected with other countries and supporting organizations to learn more
and to be able to address those issues appropriately.
• Group II. -- Vietnam, Thailand and Nepal
Mr. John Ware, a facilitator of the group, presented discussion outcomes on Vietnamese
Government’s decision to implement GPP on a compulsory basis within a short period of time.
The group felt that it could be successful if the following issues were considered seriously:
o Government financial assistance should be provided to the existing majority

pharmacies to alleviate high cost problem associated with an upgrade of pharmacies
up to a legally required size.
o Check list should be developed from the statue and used as a tool for inspectors during
the inspections and for pharmacies during the development period.
o For an initial phase, inspectors should assume a role of an educator. This could help
fasten the development period.
o Well publicity should be accomplished to communicate the Government’s expectation
o Vietnam Pharmaceutical Association should also be more actively involved in
constant stimulation on its members regarding the urgent need to implement GPP.
Dr. Th.F.J. Tromp, another facilitator, presented discussion outcomes of Nepal and Thailand.
The group pointed out some similar GPP situations between the two countries. They both had
legislation (although in different stages) and GPP guidelines, they faced similar problem on
low public awareness of what accredited (GPP) pharmacies were doing. However,
educational problem was quite evident in Thailand. There was not enough GPP exposure to
both students and young pharmacists. Unfortunately, connections to and commitments of the
universities were perceived on a world-wide basis as one of the key success factors.
Furthermore, the issue of GPP implementation speed was also discussed as the Vietnam’s
deadline of 2011 was quite short while the Nepal’s deadline of 20 years was quite long.
The group came to a conclusion that existing public awareness in both countries should be
elaborated and executed further to solve the problem. In addition, there should be more
14
opportunities to exchange ideas, information, tools, instruments, publications and documents
among participating countries.
• Group III. -- Lao PDR, Indonesia and Bhutan
Dr. Tom Ahaditomo, a group facilitator, reported discussion outcomes of Lao PDR, Indonesia
and Bhutan. After discussing the situation and policy & plans, the group concluded on
common needs of GPP guideline documents, expert supports and regular communications
with SEARPharm Forum. These needs could help them obtain GPP recognition, definite
policy, model and plan of actions. In addition, they also discussed sources of support from
local, regional and international bodies.
• Group IV. -- Cambodia and Sri Lanka
Mr. Prafull D. Sheth, a group facilitator, presented discussion outcomes of Cambodia and Sri
Lanka. The group agreed on four key drivers to GPP implementation as follows: a) National
Health Policy, b) National Medicine Policy, c) Essential Drug List and d) a linkage to GPP
through an accredited pharmacy system and a health insurance scheme. Mr. Prafull D. Sheth
further presented on situation, plan & policies, it seemed that both countries experienced
difficulties in GPP implementation. Major needs that they had to focus on, in order to
alleviate those difficulties were: a) strengthening legislation and enforcement, b) improving
quality of pharmacists through universities and continuing education programs and c) self
regulating through Pharmacy Council. In terms of local sources of support, governments,
councils and associations were discussed while SEARPharm Forum, FIP and WHO were
recognized as their regional and international sources of support, respectively.
3.7 Supporting Organization’s Role & Responsibilities in GPP
Four supporting organizations presented their role and responsibilities in GPP development
and implementation as follows:
• World Health Organization (WHO)
Dr. Kris Weerasuriya, Regional Advisor, Essential Drugs and other Medicines, South-East
Asia Region, WHO, illustrated WHO role in the development of GPP. The role of
pharmacists in the health care system was discussed in several WHO meetings, i.e., in 1988,
1993 and 1994, respectively. Within WHA 47.12 (May 1994), pharmacists and their
professional associations everywhere were called upon to support WHO Revised Drug
Strategy by practicing professional services, i.e., GPP in short.
15
Dr. Kris Weerasuriya added that GPP was part of the quality in health care delivery and could
show its value for money in terms of saving the increasing cost of health care. This saving
could gain attention from policy-makers. Only when pharmacists were recognized as a
profession and their services were included in the comprehensive health care scheme, i.e.,
medicinal costs and professional fees were available for pharmacists providing services, GPP
could be achieved in South East Asia Region. Although achieving a professional status for
pharmacists was a long–term objective, pharmacists could and should further practise GPP as
best as possible.
• International Pharmaceutical Federation (FIP)
Dr. Th (Dick) FJ Tromp, Vice President FIP, familiarized the audience with the role and
responsibilities of FIP on GPP development and implementation. As FIP recognized GPP as
the way to implement pharmaceutical care and to increase patient (medication) safety, FIP
supported GPP in several ways either alone, in collaboration with and/or endorsement by
WHO. Examples included: a) issuing and revising statements on GPP and other documents,
e.g., documents on “GPP in Community and Hospital Pharmacy Settings” and “GPP in
developing countries, b) developing Regional Pharmaceutical Forums on a world-wide basis,
c) piloting an FIP’s GPP Outreach Programme in selected developing countries, e.g., in
Thailand and Uruguay, then, marketing lessons learnt and benefits of GPP to WHO and the
“World” and d) organizing a toolbox of reference materials on GPP. FIP’s member
organizations and individual members could apply those statements and documents as well as
utilize FIP unique networks to their fullest benefits.
• South East Asia Pharmaceutical (SEARPharm) Forum
Dr. Tom Ahaditomo, President of SEARPharm Forum, stated that development and
enhancement of GPP was one of SEARPharm Forum objectives as it could improve health in
South-East Asia Region. Therefore, SEARPharm Forum encouraged an implementation of
pharmacy service and pharmacy practice projects by National Pharmaceutical Associations.
He also presented the Forum’s eight next steps to implement GPP policy and plans in South
East Asia Region:
o Close dialogue and cooperation on GPP programmes between FIP, WHO and member
associations
o Work with local governments and National Pharmaceutical Associations in GPP

development and implementation
o Facilitate an implementation of pharmacy practice through projects at national level
16
o Integrate WHO policies to the basic, postgraduate curriculum and continuing
education of pharmacists
o Measures for development and implementation of pharmacy accreditation
o Formulate policy statements on health issues of concern to pharmacists
o Monitor and update database yearly in Forum ExCo
o Seek cross border collaboration between Forums
Dr. Tom Ahaditomo expected to further define and promote GPP model developed from this
Bangkok conference and put it into practice in the near future (3-year period).
• Western Pacific Pharmaceutical Forum (WPPF)
Mr. John Ware, President of WPPF described the Forum’s objectives of supporting GPP,
quite similar to those of SEARPharm Forum. WPPF realized the language difference within
the region; therefore, GPP documents developed were translated into many languages to
ensure understanding. In addition, part of each ExCo meeting was scheduled to discuss GPP.
Mr. John Ware also showed the audience some pictures of GPP promotional materials used in
different member countries.
In addition, Mr. John Ware mentioned some good observations derived from the Forum’s
experience in supporting several country programs. Good advice, networking and self
initiation could move the project better than just waiting for financial support. Furthermore,
international network could have a profound impact on the governments/decision-makers.
3.8 Support, Collaboration and Implementation Mechanism
As already mentioned in section 1.3: Expected Outcomes, there was a change in the program.
Basket exercises were initiated to produce concrete and practical strategies and tactics on GPP
development and implementation as well as networks of countries with common strategies
and tactics. It was expected that the identified networks could further promote supports and
collaborations within the regions.
Issues/problems identified during the conference were grouped and put in six (originally
planned for five) baskets for further discussion as a team. Those baskets were:
• Changing perception of the role of pharmacists among themselves
• Improving the quality of pharmacy practice
17
• Documentation and dissemination of the value and benefits for the society and the
patients of pharmacies in the supply chain
• Raising public awareness of the added value of the role of pharmacists/pharmacies
• The role of the associations/forums
• Educations
Under the guidance of Mr. Kurt Fonnesbaek Rasmussen and Dr. Th (Dick) FJ Tromp, the
whole group of participants brainstormed and concluded on strategies and tactics that
addressed the identified issues/problems; then, signed up for participation as follows:
• Basket I: Changing perception of the role of pharmacists among themselves
Interested Countries
# Items SEA Western Pacific

Bhu Indi Indo Mal Nep Sri Tha Cam Jap Lao Mon Viet
1 Attitude of -- -- -- 3 3 3 3 3 -- 3 3 3
pharmacists
2 Consensuses between 3 -- 3 -- 3 -- 3 -- -- 3 -- --
stakeholders
3 Tie-up with -- -- -- -- -- -- -- -- 3 -- -- 3
institutions /
influencing education
4 Update knowledge 3 3 -- 3 3 3 -- -- 3 -- 3 3
of pharmacists
5 Communication skills -- -- -- -- -- -- -- -- -- -- 3 3
of pharmacists
6 Change -- -- -- -- -- -- 3 3 -- -- -- --
management
7 Role models -- -- 3 -- 3 -- 3 -- -- -- -- --
8 Support by owners -- -- -- -- -- -- -- 3 -- 3 -- --
of pharmacies
9 Seven star -- -- -- -- -- -- -- -- -- -- -- 3
pharmacist concept
18
• Basket II: Improving the quality of pharmacy practice

1 Setting standards -- -- -- -- 3 -- -- 3 3 -- 3 --
2 Institutionalizing -- -- -- -- 3 3 3 -- 3 -- -- 3
pharmacy services
(promote the strategy
of GPP)
3 Accreditation of -- 3 -- -- 3 -- -- 3 -- -- 3 --
quality/GPP
pharmacies
4 Education in GPP 3 -- 3 -- -- 3 -- 3 -- 3 3 3
implementation
5 Enforcement of 3 3 -- 3 -- -- 3 -- -- -- -- --
existing regulations
and updating
standards
6 Process of -- -- 3 -- -- -- 3 -- -- -- -- 3
implementation of
standards (e.g., TQM)
7 Increasing networking -- -- -- -- -- -- -- -- -- -- -- 3
within pharmacy
groups and outside
8 Promote small -- -- -- -- -- -- -- -- -- -- -- --
success stories
9 Benchmarking and -- -- 3 -- 3 -- -- -- -- -- -- --
transfer of best
practices
10 Defining Job -- -- -- -- -- -- -- -- -- 3 3 --
description
11 Consensuses -- -- -- -- -- 3 -- -- -- 3 -- --
between stakeholders
19
• Basket III: Documentation and dissemination of the value and benefits for the
society and the patients of pharmacies in the supply chain

1 Impact of GPP -- -- -- -- 3 -- -- 3 -- 3 -- 3
2 Consensuses between 3 -- 3 -- 3 3 -- -- -- -- 3 --
stakeholders
3 Collaboration -- 3 3 -- -- 3 3 3 3 -- -- 3
between
pharmaceutical
bodies and
universities
4 Collaboration between -- -- -- -- -- -- 3 -- -- -- -- --
pharmaceutical bodies
& universities (exploit
research in GPP)
5 Integration between -- -- -- -- 3 -- -- -- 3 3 -- 3
clinical & social
science
6 Small success -- 3 -- 3 3 -- -- -- -- -- 3 --
stories
7 Bringing outcomes of -- -- -- -- 3 -- -- 3 -- 3 -- 3
scientific activities to
the general public in
the area of GPP
20
• Basket IV: Raising public awareness of the added value of the role of
pharmacists/pharmacies

1 Increasing the role -- -- 3 -- 3 -- -- -- -- 3 -- --

of pharmacists in
health care system
2 Rational drug use 3 -- 3 3 3 3 3 3 -- 3 3 3

awareness to the
public
3 Pharmacists as a -- -- -- -- 3 -- 3 -- 3 -- -- --
health promoter
4 Survey patients and -- -- -- -- 3 -- 3 -- -- -- -- --

other health care
providers on
expectations and
satisfaction
5 “Ask your -- 3 -- -- -- -- -- -- -- -- 3 3
pharmacists about
medicines” campaign
(Associations)
6 Campaign on special -- -- -- -- -- -- 3 -- -- -- 3 --
week/day on “World
Pharmacy Day” dealing
with special issues
7 Promotion together 3 3 3 3 3 3 3 3 3 3 3 3
with new activities
8 Change of attitude of -- -- -- -- -- 3 3 -- -- 3 -- 3
pharmacists to be
more open about
pharmacy/pharmacist
activities
9 Creating drug 3 -- -- -- -- -- -- 3 3 -- -- --
information centres
10 Educate patients -- 3 -- -- 3 3 -- 3 3 3 3 3
about their rights in
pharmacy
21

11 Introduce concepts -- -- -- -- -- -- -- -- 3 -- -- 3
like “home
pharmacy”
12 Consensuses -- -- 3 -- -- -- -- -- -- -- -- --
between stakeholders
• Basket V: The role of the associations/forums

1 Negotiation & -- 3 -- -- 3 -- 3 -- 3 -- -- 3
representation for
the advancement of
the profession
2 Defining Job -- -- 3 -- 3 -- -- -- -- 3 -- --
description
3 Separation of the role -- -- -- -- -- -- 3 3 -- -- -- 3

between pharmacists
and physicians &
research into the
impact
4 Networking with 3 -- -- -- -- 3 3 -- -- 3 3 --
national and
international bodies
5 Set standards / -- 3 -- -- 3 3 -- -- 3 3 3 --
guidelines
6 Support in -- -- 3 -- 3 3 -- -- -- -- 3 --
implementation,
motivation,
education, etc.
22

7 Use associations as a -- -- -- -- -- -- -- -- -- -- -- --
database/center for
public information
on pharmacy practice
at a national level
8 Establish / review / -- -- -- -- -- -- 3 -- -- -- -- 3
renew implementation
strategies
9 Incentives for -- -- -- -- -- -- -- -- -- -- -- --
pharmacies
maintaining GPP
10 Ethics and code of -- -- -- -- 3 -- -- 3 -- -- -- 3

practice
11 Sustainability of -- -- -- -- 3 -- 3 -- -- 3 -- 3
SEARPharm Forum
- GPP projects
12 Consensuses -- -- -- -- -- -- -- -- -- -- -- --
between
stakeholders
• Basket IV: Educations

1 Competency based 3 -- 3 -- 3 -- -- 3 -- 3 3 3
curriculum
2 Mindset -- -- -- -- 3 -- -- -- -- -- -- --
reorientation of
faculty staff
23

3 Close collaboration -- -- -- -- -- 3 3 -- 3 -- -- --
between
pharmaceutical bodies
and university staff
4 Practice oriented -- -- 3 -- 3 3 -- -- -- -- 3 --
teachers
5 Workforce issues -- 3 -- -- -- -- -- -- -- -- -- --
6 Pharmacists’ support 3 -- -- 3 -- 3 -- 3 -- 3 -- 3
staff training (skill
mix issues)
7 Practice oriented -- 3 3 -- 3 -- 3 -- -- -- -- --
curriculum
8 Continuing -- 3 -- -- -- 3 3 3 -- 3 3 3
professional
development, self-
training materials, etc.
9 Consensuses -- -- -- -- -- -- -- -- -- 3 -- --
between
stakeholders
10 Ethics and code of -- -- -- -- 3 -- -- -- -- -- -- 3

practice
In conclusion, 6 strategies and 61 tactics were collectively identified. Individual countries

were encouraged to start working on the strategies and tactics signed up. They could also
consult and/or share ideas with other countries of common interests and the four supporting
organizations.
24
3.9 GPP Strengthening Plans
Dr. Songsak Srianujata presented a series of pictures portraying stories of GPP project
activities in Thailand from the founding period until the present time. Then, he invited Dr.
Tom Ahaditomo, President of SEARPharm Forum to read out the “Bangkok Declaration on
Good Pharmacy Practice in Community Pharmacy Settings” to the audience.
Representatives from all participating countries and supporting organizations signed up to
render their support to the Bangkok declaration”
Those representatives were from:

• SEARPharm Forum
○ Bhutan ○ India ○ Indonesia ○ Maldives
○ Nepal ○ Sri Lanka ○ Thailand
• Western Pacific Forum
○ Cambodia ○ Lao PDR ○ Mongolia ○ Vietnam
○ Taiwan (signed at a later stage)
• Supporting Organisations
○ FIP ○ SEARPharm Forum ○ Western Pacific Forum
All participating countries and supporting organizations agreed to harmoniously pursue the
following policy on GPP in the community pharmacy settings in their countries:
• Collaborate to create best practices according to the guidelines established by FIP and
WHO and adapt them to fit within their own national context
• Develop and implement GPP as one of the major steps to integrate community
pharmacists as a partner in the health care team of the national health policy in their
country
• Establish and strengthen collaborations among participants
• Acquire cooperation among all stakeholders and sectors, both government and private,
providing pharmaceutical services to achieve full potential of medicines during
distribution, storage and dispensing
Then, Dr. Kris Weerasuriya, Regional Advisor, Essential Drugs and other Medicines, South
East Asia Region, WHO, was invited to convey an official closing remark. Based on WHO
objective, i.e., “Better health for the population that it serves”, he addressed his satisfaction on
what had been achieved at the conference as follows:
• The conference was quite successful in terms of increasing awareness on GPP,
discussing GPP policy and plans and creating a community of pharmacists whose
physical area of work served about half of the World population.
25
• The conference was a beginning of the first step towards achieving a professional
status for pharmacists. This is because practicing GPP is one of the tools that could
demonstrate an obvious value for money of pharmacist’s role in: a) the health care
system, b) the WHO Revised Drug Strategy and c) the better use of medicines
Although what could be achieved after this conference depended upon each participating
countries, Dr. Kris Weerasuriya was quite satisfied that at least plans and efforts to develop
and implement GPP were evident at the conference. Finally, he expressed his best wishes and
a sincere support to the audience.
Before the meeting was adjourned, three individuals conveyed their gratitude. First, Dr.
Songsak Srianujata, on behalf of the organizing committee, thanked participating
organizations and individuals for their contribution and support on the conference. Second,
Mrs. Manjiri Gharat from Indian Pharmaceutical Association – Community Pharmacy
Division thanked the organizing committee, staff and facilitators on behalf of all participants.
Third, Dr. Peter J. Kielgast, Chairman, FIP Foundation for Education and Research, expressed
his great experiences on GPP in this part of the World. Those experiences were: a) the
formation and growth of the two fora, b) Thailand’s commitment, effort and hard work on
GPP development and implementation which could be recognized as a show case and a role
model for collogues and c) a strong advocacy role of WHO officials, especially Dr. Kris
Weerasuriya. Finally, Dr. Peter J. Kielgast concluded by encouraging the audience that
although GPP development and implementation was not easy but the results could be
achieved one day.
3.10 Open Discussion
An open discussion session on a boat cruising along the Chao Phraya River was arranged for
all participants. This offered opportunities for them to discuss GPP issues within and beyond
the scope of the conference openly and informally. Even though not all participants could
participate, individuals on board were seen to enjoy discussing their unsolved issues.
3.11 Field Visits
About 30 participating individuals were divided into 5 groups; each group had a chance to
visit two community pharmacies, accredited by the Thailand Pharmacy Council. Participants
were offered an opportunity to join each pharmacy briefing, observe services provided and
ask community pharmacists at the pharmacies.
26
4. Conclusion & Recommendation
The conference was mostly run as originally planned. Participants were provided with several
pieces of useful information. Examples included: GPP status in South East Asia Region,
experiences on GPP development and implementation from several countries, GPP policy and
plans of several countries including role and responsibilities of supporting organizations.
Even though some changes occurred, they were still in line with the original plans and even
broaden participant’s perspectives. Six strategies and 61 tactics to develop and implement
GPP were collectively identified via basket exercises. In addition, network of countries with
common interests were also achieved. This helped participants gain more confidence in
developing and implementing GPP in their own country. As a result, Bangkok Declaration on
GPP in Community Pharmacy Settings: a Regional GPP policy was agreed and endorsed by
all participating countries.
In general, successful GPP development and implementation takes time, effort, commitment
and collaboration among all parties involved and the dynamics within each participating
country. Therefore, it is highly recommended that constant stimulation should take place to
accelerate an application of the conference outcomes. This can be accomplished through
either follow-up or experience-sharing sessions.
27
Annex 1: Self-Assessment Questionnaire
This self assessment questionnaire is part of collaborations among South East Asian countries to promote health and well-being of the population via
a development and an implementation of “Good Pharmacy practice (GPP)” in community pharmacy settings. To this end, information on the GPP
status in each country is needed to determine a unified GPP mobilisation direction at both regional and country levels at a conference on “GPP
Policy and Plans for the South East Asia Region” in Bangkok around June-end..
Therefore, please answer this questionnaire as best as you can and return via e-mail by May 17th. Only the truth can help us mobilise GPP within the
region as effectively and efficiently as possible. As well, please be assured that information uncovered will be kept confidential and will be used to
serve the above stated purpose only.
I. Contact Person Information

Name………………………………………………….. Title………...………………………. Organisation………………………...….……….
Address………………………………………………………………………………………..……………………………………..…………….
………………………………………………..…….… Country…………………………..….…. Zip Code………..…..………………
Tel……………………….….... Fax……………….………….. Website………….…...………………… E-mail……………….……..…….…
II. Respondent Information
# Name Title Organisation Remarks

1
2
3
Date of response:……………………………………………………..……..
28
III. Country Information
3.1 General Information (in 2006 2005 2004 …....)
3.1.1 Total Population:…………..……………..…… million persons 3.1.2 Population Growth Rate: …………………………..……..…%
3.1.3 Country Area:…………………………….….............….. sq.km. 3.1.4 GDP:………………………………………………...… US$*
3.1.5 Per Capita Income:…………………………………….. US$* 3.1.6 Average Drug Expense / person:………….……...…… US$*
Note: *exchange rates:………………………….
3.2 Quality Control Information
3.2.1 Are there any quality control systems on drug manufacturing in your country?
no y What do drug manufacturers rely on? ………………………………………………………………..………………..
yes y What are they? GMP PIC/S Others……………………………………...….. (Please specify)
y Are they required by laws? no yes
y Are they well observed? no yes
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
29
3.2.2 Are there any quality control systems on drug inventory & transportation in your country?
no y What do drug suppliers / pharmacy owners rely on? …………………………………………………………...……..
yes y What are they? ……………………………………………………………………………………………………..…..
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
3.2.3 Are there any quality control systems to minimise drug counterfeits in your country?
no y What do pharmacy owners / pharmacists rely on? …………………………………………………………...........…..
yes y What are they? ……………………………………………………………………………………………………..…..
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
3.2.4 Is there a “National Drug List for Pharmacies” in your country?
no y What do pharmacy owners / pharmacists rely on? ……………………………………………….……………………
yes y Are they required by laws? no yes
• Are they well observed? no yes
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
30
3.2.5 Are there any “National Drug Procurement Policy and Procedures for Pharmacies” in your country?
no y What do Pharmacy owners / pharmacists rely on? ……………………………………………….……………………
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
3.2.6 Are there any “National Policy and Procedures for Reporting Incidents” in your country? Examples of incidents include adverse
drug reactions and avian flu outbreaks.
no y What do Pharmacy owners / pharmacists rely on? ……………………………………………….……………………
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
3.2.7 Does pharmacy accreditation exist in your country?

no y What is the quality control system currently used? ………………...………………………………………..….……..
yes y Who is responsible for the accreditation process?.…………………………………………………………….....….....
y Is it required by laws? no yes
y How many accredited pharmacies are there in your country at this moment? ……………………...…………………
Comments: ………………………………………………...………………………………………………………………………...
………………………………………………………………………………………………………………………………………..
31
3.3 Prescription System Information
3.3.1 In your country, where does the population have his/her prescriptions filled? And at what percentage?
Hospital …..……% Clinics…..……% Community Pharmacies …..……% Others …..……%
3.3.2 If the prescriptions are now being filled at community pharmacies:
3.3.2.1 Do the following quality control systems exist? How are they accomplished? Are they well observed?
Are they well observed?

QC Systems How are they 0% 1- 26- 51- 76- Remarks
(Y/N) accomplished? 25% 50% 75% 100%
Rational use of drug
prescribed
Generic drug
substitution
Double checking
with prescribers
Double checking on
pharmacy service
32
3.3.2.2 What are the advantages of filling prescriptions at community pharmacies?
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
3.3.2.3 What are the disadvantages of filling prescriptions at community pharmacies? What needs to be improved? And how?
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
33
3.3.3 If the prescriptions are now not being filled at community pharmacies:
3.3.3.1 In your opinion, should they be filled? Why?
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
3.3.3.2 Does you country have a policy to promote access to prescription medicine via community pharmacy channel? And what is
the current status?
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
34
3.4 GPP Information
3.4.1 From your country’s perspective, are there any endeavours to define GPP?
no
yes y Who is/are responsible? ………………………………………………………………...……………………………...
y What is your definition of GPP? …………………………………………………..…………………………………...
…………………………..………………………………………………………………………...…………………...
…………………………..………………………………………………………………………...…………………...
…………………………..………………………………………………………………………...…………………...
3.4.2 From your country’s perspective, are there any endeavours to develop GPP?
no
y What is the current status? ………………………….……………………………..…………………………………...
…………………………..………………………………………………………………………...…………………...
…………………………..………………………………………………………………………...……………….…...
…………………………..………………………………………………………………………...…………….……...
35
3.4.3 From your country’s perspective, are there any endeavours to implement GPP?
no
y What is the current status? ………………………….……………………………..…………………………………...
…………………………..………………………………………………………………………...…………………...
…………………………..………………………………………………………………………...…………………....
…………………………..………………………………………………………………………...…………….……...
3.5 Legislation Information
3.5.1 Are there any legislations controlling the following items in your country?
Drug related
Manufacturing Registration Costs of local drugs Costs of imported drugs
Advertising Distribution/Selling Post marketing Others ………………………….
……………………………………………………………………………………………….………………………
……………………………………………………………………………………………….…….. (Please specify)
36
How many types of drugs legally sold in community pharmacies? What are they? Any required selling conditions?
# Types of Drug* Selling Conditions Remarks

1
2
3
4
5
…
*Note: Types of Drug Sold = Prescription drugs, Pharmacist’s supervision only, OTC, etc.
Community Pharmacy related

Registration
• How many types of community pharmacy registration are there in your country? What are they?
# Types of Community Types of Qualifications** Remarks

Pharmacy Registration Drug Sold* Owners Operators
1
2
3
4
5
…
Note: * Please refer information from the previous table
** Qualifications = Investor, Health Professionals, e.g., Medical Doctors, Pharmacists, Nurses, etc.
37
• Which organisation is responsible for community pharmacy registration? …………………………..…………….
…………………...……………………………………………….…………………………………………….……
Renewal
• How long is the renewal period? ……………………………………………………………………………………
• Which organisation is responsible for community pharmacy renewal? …………….………………..…………….
…………………...……………………………………………….…………………………………………….……
• Is renewal automatically applied?
no What are the conditions for renewal?...............................................................................................
……………………………………………………………………………………………………..
……………………………………………………………………………………………………..
yes
Pharmacist related
Licensing
• Is licensing of pharmacists required in you country?
no
yes What are the conditions for licensing?.............................................................................................
……………………………………………………………………………………………………..
……………………………………………………………………………………………………..
• Which organisation is responsible for issuing licenses? ……………………..……….………………..……………
• How long is the licensing period? ……………………………………………………………………………...……
38
• Is renewal automatically applied?
no What are the conditions for renewal?...............................................................................................
……………………………………………………………………………………………………..
……………………………………………………………………………………………………..
yes
Ethics: Which organisation is responsible? …………………...………………………….………………………………
Disciplinary actions: Which organisation is responsible? …………………...…………………..………………………
3.5.2 Are those legislations sufficient to produce / promote quality pharmacy services? What should be done to improve the situation?
………………………………………………………………………………………………………………………..……………...
……………………………………………………………………………………………………….………………….…………...
……………………………………………………………………………………………………………………….………….……
…………………………………………………………………………………………………………………………..…………...
39
3.5.3 Are those legislations well observed and enforced? What should be done to improve the situation?
………………………………………………………………………………………………………………………..……………...
……………………………………………………………………………………………………….………………….…………...
……………………………………………………………………………………………………………………….………….……
…………………………………………………………………………………………………………………………..…………...
3.5.4 Are there many lawsuits relating to services provided in community pharmacy in your country? What are the top five most
frequent cases?
………………………………………………………………………………………………………………………..……………...
……………………………………………………………………………………………………….………………….…………...
……………………………………………………………………………………………………………………….………….……
…………………………………………………………………………………………………………………………..…………...
40
IV. Community Pharmacy Related Information
Community Pharmacy is defined as an area of pharmacy practice in which medicines and other related products are sold or provided directly to
the public from a retail (or other commercial) outlet designed primarily for the purpose of providing medicines. The sale or provision of the
medicine may be either on the order or prescription of a doctor (or other health care worker), or “over the counter” (OTC).
4.1 Attitude towards Community Pharmacy
4.1.1 Population’s Attitude towards Community Pharmacy

Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
Approximated quantity of health conscious population
Approximated quantity of price sensitive population
How well is the relationship between the population and
community pharmacy settings?
How well is the population aware of the roles and
responsibilities of community pharmacists?
How well is the population’s attitude towards community
pharmacists?
How well does the population call for community
pharmacists when requiring services from community
pharmacies?
How well does the population demand good pharmacy
practice from community pharmacists?
41
4.1.2 Physician’s Attitude towards Community Pharmacy Practice
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
How well is physician’s attitude towards services provided
by community pharmacists?
How well is the professional relationship between
physicians and community pharmacists?
4.2 Personnel Information
4.2.1 Information on Personnel Number, Training / Education & Licensing Requirements (in 2006 2005 2004 …....)
Number Training / Education Licensing

Types of Requirements
Personnel* # #/ Trained # of Certified Credentials CE² Yes / Licensing
100,000 by..+ Years by.. + Received++ (Y/N) No Body
pop.
Community
Health Care
Worker
Unqualified
Pharmacy
Technician
42
Number Training / Education Licensing
Types of Requirements
Personnel* # #/ Trained # of Certified Credentials CE² Yes / Licensing
100,000 by..+ Years by.. + Received++ (Y/N) No Body
pop.
Qualified
Pharmacy
Technician
Pharmacist
Notes:
* Community Health Care Worker: A person who is trained to provide simple, low level health care commensurate with the level
of training.
Unqualified Pharmacy Technician: A person who is involved in the dispensing of medicine, but who has only received “on the
job” or “in house” training.
Qualified Pharmacy Technician: A person with formal dispensing training (at a lower level than a pharmacist) involved in the
dispensing of medicines. (The training or at least a part of it, would have taken place at a
recognised training institution and a certificate or license would have been issued.)
Pharmacist: A person with a formal higher qualification such as a three-year (minimum) university
degree or diploma in pharmacy
+
Trained / Certified by..: Professional Pharmaceutical Body, University or Others (please specify)
++
Credentials Received: Certificate, Diploma, Degree - Bachelor/ Master or Others (please specify)
²
CE: Continuing Education: The responsibility of individual persons for systematic maintenance, development and
broadening of knowledge, skills and attitudes, to ensure continuing competence as a
professional, throughout their careers.
43
4.2.2 Educational Contents Related to Community Pharmacy Provided to Pharmacists
Topics/Subjects # of Comments
Educational Level Name Descriptions Status Graduates
(in theYear
………..….)
Bachelor Degree Good Pharmacy Guidelines on GPP in Required
(General) Practice (GPP) community pharmacy Electives
settings Not Available
Community Technical & business Required
Pharmacy management Electives
knowledge Not Available
Pharmaceutical Technical knowledge Required
Care Electives
Not Available
Bachelor Degree Pharmaceutical Technical knowledge Required
(Pharm D) Care Electives
Not Available
44
4.2.3 Qualifications of Pharmacists Working in Community Pharmacy Settings
Required Current Practice

Qualifications by Laws Yes No Remarks
(yes/no)
Degree:
• Bachelor Degree in Pharmacy
• Bachelor Degree, specialised in Community
Pharmacy or Pharmaceutical Care
• Master Degree, specialised in Community
Pharmacy or Pharmaceutical Care
Active License
4.2.4 Educational Capacity
4.2.4.1 How many Universities / Educational institutions that can produce legally qualified pharmacists to work in community
pharmacy settings are there in your country? ……………………………………………………………………………............
4.2.4.2 What is the total growth rate of those pharmacists per year? ........................................................................................................
4.2.4.3 What is the latest ratio of those pharmacists to community pharmacy settings? …………………………… (In the year 200...)
45
4.2.5 Professional Development & Regulation
4.2.5.1 Organisations that have authority to develop and regulate pharmacists working in community pharmacy settings:
Authority areas Organisations Remarks

Training & Development
Public Relations
Recognition & Awards
Disciplinary Actions
Other…………………….……(Please specify)
Other…………………….……(Please specify)
46
4.2.5.2 Which organization has gained the most respect from all pharmaceutical bodies? And why?
…………………………………………………………………………………………………………………………………...
…………………………………………………………………………………………………………………………………...
…………………………………………………………………………………………………………………………………...
4.2.5.3 Which organization is the most appropriate body to promote GPP in your country? And why?
…………………………………………………………………………………………………………………………………...
…………………………………………………………………………………………………………………………………...
……………………………………………………………………………………………………………………………………
4.3 Financial Information
4.3.1 Drug Expense in Community Pharmacy
4.3.1.1 Average drug expense in community pharmacy / patient …………………….. US$ (exchange rates:………………………….)
47
4.3.1.2 What are the remuneration systems for drug expense in pharmacy?
Out-of-pocket From private insurers From government
Others …………………………………………………………………………………………………..(Please specify)
4.3.2 Source of Income
Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
Drugs
• Prescription Drugs
• Non-Prescription Drugs
Professional fees from the following services:
• Prescription review
• Dispensing
• Generic substitution
• Extemporaneous preparation
• Counselling
• Chronic disease management
• Disease screening programs
• Smoking cessation
• Follow-up
• Home health care
• Others ………………………………….…….
• Others ………………………………….…….
Other pharmaceutical products
Non-pharmaceutical products
48
4.3.3 Level of Income
4.3.3.1 Is community pharmacy considered as a good business investment in your country?

0% 1-25% 26-50% 51-75% 76-100%
Comments……………………………………………………………………………………………………………………..
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………
4.3.3.2 Are there any financial incentives for community pharmacies to provide the best possible pharmaceutical care to the
population?
no
yes What are they? ……………………………………………………….………………...……………………………...
………………………………………………………………………………………………………………...……
………………………………………………………………………………………………………………...……
49
4.4 Community Pharmacy Information
4.4.1 Community Pharmacy Information by Types of Owner (in 2006 2005 2004 …....)
Number Distribution Growth Rate Remarks

Types of Pharmacy # % % % (%) / year
Urban Rural
Stand Alone ---
• Pharmacist-Owned ---
• Investor-Owned --
• State-Owned --
Franchise --
Other:…………….….… (Please specify) --
Other:……………..…… (Please specify) --
Total Number 100 100 100 ………...
50
4.4.2 Community Pharmacy Information by Pharmacist’s Hours of Operations (in 2006 2005 2004 …....)
Number / Ratio Distribution

Types of Pharmacy # # / 100,000 % % Remarks
population Urban Rural
Pharmacies with pharmacists all working hours
Pharmacies with pharmacists some working hours
Pharmacies with no pharmacists on duty Legally acceptable = …..…..
Illegal = ……………………
Other:……………...…….…… (Please specify)
Total Number 100 100
4.4.3 Types of Service Provided

Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
Provision of prescription medicine
Provision of non-prescription medicine for minor
illness
Extemporaneous preparation
Drug Counselling
Drug monitoring within community pharmacy
settings
Provision of advice on health promotion and disease
prevention, e.g., smoking cessation
51
Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
Working with other health and social care
professional
Community pharmaceutical service, e.g., home health
care
Others …………………………………….………….
Others …………………………………………….….
4.4.4 Premises and Facilities Available
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
A strong building, separated from the surrounding
areas
Cleanliness, tidiness with hygienic conditions
Well protection from exposure to excessive light and
heat, e.g., refrigeration available
An area suitable for servicing and counselling,
provided or identified
A separate, confidential room or facility for servicing
and counseling, provided
52
4.4.5 Equipment Available
Equipment Required Current Practices Remarks

by Laws 0% 1-25% 26- 51- 76-
50% 75% 100%
Medicine trays
Medicine Containers
Labels
Auxiliary labels
Follow-up cards
Refrigerators
Bath Scales
Height Scales
Blood pressure monitoring device
Glucometer
Reference materials, e.g., standard
medicinal treatment guidelines
Internet access
Knowledge brochures
Knowledge boards
Others...................................................................
Others...................................................................
Others...................................................................
53
4.5 Management Issues
4.5.1 Attitudinal Issues
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
How well is community pharmacy owners’ attitude
towards community pharmacists?
How well is community pharmacists’ attitude
towards community pharmacy services?
How well is community pharmacists’ attitude
towards GPP in community pharmacies?
4.5.2 Management of Business Operations
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
At what level are practising community pharmacists
involved in decision-making process of the following
areas:
• Pharmacist-Owned Community Pharmacies
o Business related
o Professional service related
54
Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
• Investor-Owned Community Pharmacies
o Business related
• State-Owned Community Pharmacies
o Business related
4.5.3 Management of Service Provided
4.5.3.1 Instructions & Labelling
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
Only verbal instructions provided
Verbal instructions and labels affixed to drug
containers
Verbal instructions, labels affixed to drug
containers and counselling
Verbal instructions, labels affixed to drug
containers, counselling and information
leaflets provided
55
Items 0% 1-25% 26- 51- 76- Remarks
50% 75% 100%
Labelling information on drug containers:
• generic name
• strength
• dose
• drug regimen
• duration of course
• date of dispensing
• name of patient
• name of pharmacy
Label preparation
• manual
• printing
56
4.5.3.2 Drug Containers Utilised
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
Air-tight plastic envelops/bags
Air-tight, rigid containers, e.g., bottles
Air-tight, rigid containers with a child
resistant closure
Manufacturer’s original packaging
Others…………...….. (Please specify)
Others…………...….. (Please specify)
4.5.3.3 Are there any systems set up to ensure quality of service provided?
4.5.3.3.1 Are there any double-checking systems to confirm accuracy of service provided?
no
yes What are they? ………………………………………………………………………………………..
……………………………………………………….…………………….....………….……………
………………………………………………………………………………………………………...
57
4.5.3.3.2 Are there any standard operations procedures (SOP) available in the pharmacies? Are they well observed?
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
SOP on procurement of
pharmaceutical products
SOP on temperature control
SOP on an evaluation of
prescriptions
SOP on dispensing procedures
SOP on drug counselling
SOP on patient’s monitoring
SOP on patient’s referring
Others
……………………………………
Others
……………………………………
58
4.5.3.4 Documentation & Usage
Items 0% 1-25% 26- 51- 76- Remarks

50% 75% 100%
Patient drug profiles
• Manual
• Electronic
Adverse drug reactions documented &
reported to the authorities
Incidents documented & reported to the
authorities
Others ……………………………………
Others ……………………………………
V. Open Comments
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
59
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………………………
Please e-mail back by May 17th
60
Annex 2: Conference Programme
I. June 26th, 2007—Tuesday : Arrival of delegates to the conference and SEARPharm

Forum ExCo meeting (15.00 - 17.00)
th
II. June 27 , 2007—Wednesday : Conference session
08:00 – 08:30 Registration
08:30 – 08:55 Session I: Opening Session
Welcome Remarks
• Dr. P.T. Jayawickramarajah, WHO Representative to Thailand
• Dr. Peter J. Kielgast, Chairman, FIP Foundation for Education
and Research
• Prof. Dr. Pavich Tongroach, President, The Pharmacy Council
Opening Address
• Dr. Siriwat Tiptaradol, Secretary – General, Thailand Food
and Drug Administration
08:55 – 09:15 Photo Session

• All Delegates
• All Participants
09:15 – 09:30 Session II: Presentation of GPP Status in SEA Region (Ms.
Chongmas Nitisingkarin)
09:30 – 09:45 Session III: Discussion of Proposed Regional GPP Policy (Dr.
Songsak Srianujata)
09:45 – 10:30 Session IV: Experience Sharing Session [Dr. Th(Dick)FJ Tromp]
IV.1) GPP Development and Implementation in relation to

Separation of Prescribing and Dispensing (15 mins./country)
• Japan Pharmaceutical Association
• Korean Pharmaceutical Association
• Pharmaceutical Society of China Taiwan and Taiwan Society of
Health-System Pharmacists
10:30 – 10:45 Coffee Break
61
10:45 – 12:30 Session IV: Experience Sharing Session [Dr. Th(Dick)FJ Tromp] –
continued
IV.2 GPP Development and Implementation, National Strategic Plans

and Plan of Action: Case Story (15 mins./country)
• Mongolia
• Vietnam
• Cambodia
• Lao PDR
IV.3 Measures Taken for GPP Development and Implementation,
Accreditation of Pharmacies: Country Perspective (15
mins./country)
• Australia
• India
• Thailand
12:30 – 13:30 Lunch
13:30 – 15:00 Session V: Discussion on Country’s GPP Policy & Plans

Facilitators: Mr. John Ware, Mr. Kurt Fonnesbaek Rasmussen,
Dr. Th(Dick)FJ Tromp, Dr. Peter J. Kielgast,
Dr. Kris Weerasuriya, Dr. Tom Ahaditomo,
Mr. Prafull D. Sheth and Dr. Songsak Srianujata
V.1 Plenary Discussion (13:30 – 14:15)

• Thailand
V.2 Concurrent Group Discussion (4 groups; 3 countries/group)
(14:15 – 15:00)
2.1 First four countries
15:15 – 16:45 V.2 Concurrent Group Discussion (4 groups; 3

countries/group) – continued
2.2 Second four countries (15:15 – 16:00)
2.3 Third four countries (16:00 – 16:45)
16:45 – 17:00 Session VI: Priority Setting Session on Country’s Help Needed
Areas (Dr. Songsak Srianujata)
17:30 – 20:30 Open Discussion
62
III. June 28th, 2007—Thursday : Conference session
08:30 – 9:30 Session I: Presentation of Role & Responsibilities in GPP

Development and Implementation
• WHO - Dr. Kris Weerasuriya (8:30 – 8:45)
• FIP – Dr. Peter J. Kielgast (8:45 – 9:00)
• SEARPharm Forum – Dr. Tom Ahaditomo (9:00 – 9:15)
• WPPF – Mr. John Ware (9:15 – 9:30)
09:30 – 10:30 Session II: Identification of Support, Collaborations and

Implementation Mechanism (Mr. Kurt Fonnesbaek Rasmussen and
Dr. Th(Dick)FJ Tromp)
• 3 countries (@ 20 mins.)

Implementation Mechanism (Mr. Kurt Fonnesbaek Rasmussen and Dr.
Th(Dick)FJ Tromp) – continued
12:30 – 13:30 Lunch

Implementation Mechanism (Mr. Kurt Fonnesbaek Rasmussen and Dr.
Th(Dick)FJ Tromp) – continued
15:25 – 15:45 Session III: Observations from the Project Management - What
have we achieved? (Mr. Kurt Fonnesbaek Rasmussen and Dr.
Th(Dick)FJ Tromp)
15:45 - 16:30 Session IV: Wrap-up on Plans for Strengthening of GPP in

Community Pharmacy Settings in SEA Region (Dr. Kris
Weerasuriya & Dr. Songsak Srianujata)
63
IV. June 29th, 2007—Friday : Field Visits
08:30 - 14:00 Field Visits to Thai “Quality Pharmacies” (Team)
64
Annex 3:
65
66
67
68
Annex 4: Key Participant Information
I. Participating Countries in SEARPharm Forum
1.1) Bhutan
Title Name Position Organisation Mobile/tele/fax E-mail Remarks
Ms. Ngawang Dema Pharmacist Drug Regulatory Authority, Royal 00975-17611744 ngawangdema@health.
Government of Bhutan gov.bt
Ms. Manusika Rai Senior Pharmacist Drug Vaccines and Equipment Division, 00975-17604512 msikarai@hotmail.com
Ministry of Health
1.2) India
Title Name Position Organisation Mobile E-mail Remarks
Mrs. Manjiri S Gharat Secretary IPA Community Pharmacy Division, 91 9869128246 symghar@yahoo.com Accreditation
Indian Pharmaceutical Association speaker
Mr. Raj Vaidya Vice President & Indian Pharmaceutical Association 91 9422962286 hindupharmacy@gmail GPP policy &
Chairman .com plans speaker
1.3) Indonesia
Mr. Saleh Rustandi The President Director PT Kimia Farma
Dr. Sahat Saragi Pharmacist PT Kimia Farma sahat_saragi@telkom.net
or
sahat_saragi@yahoo.com
Dr. Hendra Purnomo ISFI (National Pharmacist 62-21-345 1473, Hendra_purnomo@ind
Association) 3503921/25 o.net.id
fx: 62-21-350-5611
Mr. Imam ISFI (National Pharmacist imamfathorraman@pla
Fathorrahman Association) sa.com
1.4) Maldives
Ms. Shasma Assistant Maldives Food and Drug Authority 9607710373 xaxmax@hotmail.com
Mohamed Pharmaceutical
Officer
Ms. Aminath Assistant Maldives Food and Drug Authority 9607720866 ainthis@hotmail.com
Mohamed Pharmaceutical
Officer
1.5) Nepal
Dr. Balkrishna Registrar Nepal Pharmacy Council 9851070227 bkhakurel@yahoo.com
Khakurel
Mrs. Rajani Shrestha Nepal Bureau of Standards and Metrology +97-98412-8217 Rajani967@yahoo.com
1.6) Sri Lanka

Mr. Shalutha Athauda Senior Vice Pharmaceutical Society of Sri Lanka +94 777 636424 coo@ceylincopharma
President .com
Ms. Chinta General Pharmaceutical Society of Sri Lanka +94 777 656133 chinta@whosrilanka. Allergic to
Abayawardana Secretary org beef
1.7) Thailand
Mr. Teera President The Pharmaceutical Association of 66 08 1811 9935 teera.c@olic-thailand.com
Chakajnarodom Thailand under Royal Patronage
Dr. Pavich Tongroach President The Pharmacy Council 66 08 1372 8273 pavich@gmail.com
Mr. Prasit Wongnijasil President Drug Stores Club of Thailand 66 08 1544 5489 pharmakon_th@yahoo.com
66 08 9127 9250
Mr. Jittawut President Thai Pharmacies Association 66 08 1819 5021 --
Limsirisrethakul
Mr. Teerawudh President Community Pharmacy Association 66 08 7501 1510 superdad50@hotmail.com
Pongsretpaisal (Thailand) teerawudh@yahoo.com
pteerawudh@gmail.com
Ms. Chongmas Secretary Community Pharmacy Association 66 08 1847 9270 cnitisingkarin@gmail.com GPP status
Nitisingkarin (Thailand) smartmas@hotmail.com speaker
Dr. Wiwat Lecturer Faculty of Pharmacy, Khonkhan 66 08 9350 3131 wiwat@kku.ac.th
Arkaravichien University
Dr. Wirat Tongrod Lecturer Faculty of Pharmacy, Huachieu 66 08 7011 9168 freshwirat@hotmail.com Accreditation
Chalermprakiet University speaker
Dr. Siriwat Tiptaradol Secretary General Thai Food and Drug Administration siriwat@fda.moph.go.th
Ms. Weerawan Tangkeo Deputy-Secretary Thai Food and Drug Administration weerawan@fda.moph.go.th GPP Policy
General speaker
Mr. Visid Chief Office of Pharmacy Advancement ofphar@fda.moph.go.th
Pravinvongvuthi Project, Drug Control Division,
FDA
Dr. Duangtip Consultant Office of Pharmacy Advancement duangtip@health.moph.go.th
Hongsamoot Project, Drug Control Division,
FDA
Mrs. Sirirat Tupichart Committee Community Pharmacy Association, s_tunpichart@yahoo.com
Thailand
II. Participating Countries in Western Pacific Forum
2.1) Australia
Mr. John Ware President Western Pacific Pharmaceutical Forum 0408 349 163 peas@mcmedia.com.au Accreditation
speaker
2.2) Cambodia
Mr. Yim Yann President Pharmacist Association of Cambodia Ph 855-12-919892 yimyann@yahoo.com
fx 855-3-880696 edb.ddf@online.com.kh
Ms. Mam Boravann Officer Pharmacist Association of Cambodia ph 855-23880969 edb.ddf@online.com.kh
fx 855-23-880696
Mr. Tiv Sothearith Officer Pharmacist Association of Cambodia 855-12-75-3848 ph_sothearith@yahoo.com
shcpharmacy@online.com.
kh
Ms. Sar Lada Officer Pharmacist Association of Cambodia ph_sothearith@yahoo.com
Dr. Tep Lun Director General Ministry of Health 855-12 91 98 92 edb.ddf@online.com.kh
for Health teplun@yahoo.com
Dr. Chroeng Sokhan Deputy Director Department of Drugs and Food, 855-12 86 20 10 sokhan_c@online.com.kh
Ministry of Health edb.ddf@online.com.kh
2.3) Japan
Mr Daisuke Kobayashi Member International Affairs Committee, Japan 81-90-7905-2686 amadeus@olive.ocn.ne.jp Separation
Pharmaceutical Association speaker
2.4) Lao PDR
Dr. Sivong Head of Food and Drug Department, Ministry of 85620 2208014 sivong_sengaloundeth National
Sengaloundeth Administration Health @yahoo.com, Plans
Division drug@laotel.com speaker
2.5) Mongolia
Ms Munkhdelger, munkhdelger@moh.mn
MOH
Ms. P. Tsetsgee Officer Pharmaceuticals and Medical Devices 976-99897870 ptsetsgee@yahoo.com ?? National
Department, Ministry of Health tsetsgee@moh.mn Plans
speaker
Professor President the Mongolian Pharmaceutical Association dungerdorj@hsum.edu.mn
Dungerdorj
Dr. Tseveen Head Pharmaceutical Technology and 976-99860945 tseveen_davaasuren@yahoo.
Davaasuren Pharmacy Management Department, com
Pharmacy School, Health Sciences
University of Mongolia
2.6) Taiwan
Ms. Hsiang-Yin, Chen Director Department of Pharmacy, Taipei +886 968-718- shawn@tmu.edu.tw Separation
(Shawn) Medical University Municipal Wan- 775 speaker
Fang Hospital
Ms. Su-Yu, Chien Director Department of Pharmacy, Changhua +886 936-829- 2655@cch.org.tw
Christian Hospital 135
Ms. Mei-Ling, Hsiao Director Genernal Bureau of Health Promotion, hsiao@bhp.doh.gov.tw
Department of Health Taiwan
Prof. Weng-Foung President The Pharmaceutical Society of Taiwan +886 huang@ym.edu.tw Dinner
Huang 932955194 talk
speaker
Dr. Wen-Shyong, Liou President Taiwan Society of Health-System +886 933-223- wls@mail.ndmctsgh.edu.tw
Pharmacists 660
2.7) Vietnam
Mr. Chu Dang Trung Vice Head Division of Pharmaceutical 0903432065 chudangtrung@yahoo.com
Legislation and Policy, Drug
Administration of Vietnam
Mr. Nguyen Van Dinh Vice President Vietnam Pharmaceutical Association Vandinh_ng@yahoo.com National
Plans
Speaker
III. Supporting Organisations
3.1 WHO
Title Name Position Country Mobile E-mail Remarks
Dr. Kris Weerasuriya Regional Advisor, weerasuriyaK@searo.w
EDM ho.int
Dr. P.T. WHO Representative jayawickramarajah@se
Jayawickramarajah to Thailand aro.who.int
3.2 FIP
Dr. Peter J. Kielgast Chairman kielgastp@yahoo.com
Mr Kurt Fonnesbaek Consultant Denmark +45 2020 3920 kfr@pharmakon.dk
Rasmussen
Dr. Th.F.J. Tromp Vice President The Netherlands +31 38 3371412 tt@flevowijk.nl
Mr Xuanhao Chan Project Coordinator Singapore/Netherlands +31625066964 xuanhao@fip.org
3.3 Western Pacific Forum

Mr. John Ware President Australia 0408 349 163 peas@mcmedia.com.au
3.4 SEARPharm Forum

Dr. Tom Ahaditomo President Indonesia +62811950363 ahd@meiji.co.id
Mr. Prafull D. Sheth Professional India +91-98103-35405 pdsheth@hotmail.com
Secretary
Mr. M. V. Siva Prasada Executive Secretary India +91-98718-77117 prassu117@yahoo.com
Reddy
Mr. Subodh Priolkar ExCo Member India +91-98679-45678 subodhpriolkar@valois-
india.com
Dr. Songsak Srianujata ExCo Member Thailand 66 08 1343 3580 rassn@mahidol.ac.th
Methanee Twinprawate
methanee@fda.moph.go.th
July 4th, 2007

GPP Policy Asia Tenggara

Загружено:

Сведения о документе

Исходное описание:

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

GPP Policy Asia Tenggara

Загружено:

Авторское право:

Доступные форматы

A Conference on GPP Policy and Plans for the

South East Asia Region

Executive Summary ……………………………………………...… iv

2. Actual Outcomes ……………………………………….……………….. 2

3. Session Summary ……………………………………………...…. 3

4. Conclusion & Recommendation …………………………………27

1. Self-Assessment Questionnaire …………………………..…….. 28

As a result, the Pharmaceutical Association of Thailand under Royal Patronage in

The 13 countries to be originally focused in this conference are as follows:

1.1 General Objectives

1.2 Specific Objectives

Specific objectives expected from the conference are:

1.3 Expected Outcomes

Countries participating in the conference were:

The conference was accomplished as originally planned. However, a decision was

3.1 Inaugural Session

• Welcome remark by Dr. P.T. Jayawickramarajah, WHO Representative to

• Welcome remark by Dr. Peter J. Kielgast, Chairman, FIP Foundation for

• Inaugural address by Dr. Siriwat Tiptaradol, Secretary – General,

3.2 Reports on GPP Status in SEA

Ms. Chongmas Nitisingkarin, Secretary General of Community Pharmacy Association

Regarding information on community pharmacists in community pharmacies, survey

Based on FIP/WHO standards for community pharmacies, information on premises,

3.3 Discussion on Proposed Regional GPP Policy

Dr. Songsak Srianujata, Executive Committee Member of the SEARPharm Forum,

3.4 Experience Sharing on GPP Development & Implementation

3.4.1 Separation of Prescribing & Dispensing

Mr. Daisuke Kobayashi, Japan Pharmaceutical Association (JPA) shared experiences on

Ms. Shawn Hsiang-Yin Chen, Chairman, International Affairs Committee, Taiwan

The Separation of Prescribing and Dispensing Policy (Separation policy) was

In 1995, 38 prescriptions were released to BNHI contracted pharmacies, around 2

3.4.2 National Strategic Plan & Plan of Actions

o Lao PDR’s Experience

3.5 Measures Taken: Accreditation of Pharmacies

3.5.1 Australia’s Experience

3.5.2 India’s Experience

Mrs. Manjiri Gharat from Indian Pharmaceutical Association - Community Pharmacy

3.5.3 Thailand’s Experience

Dr. Wirat Tongrod concluded his presentation by emphasizing that stakeholder’s

3.6 Group Discussion on Country’s Policy & Plans

Under a guidance of Dr. Songsak Srianujata, Executive Committee Member of the

Group # Participating Countries Facilitators

Group I • Mongolia • Dr. Peter J. Kielgast

Mr. Kurt Fonnesbaek Rasmussen, a group facilitator, presented discussion outcomes of

• Group II. -- Vietnam, Thailand and Nepal

o Government financial assistance should be provided to the existing majority

• Group III. -- Lao PDR, Indonesia and Bhutan

• Group IV. -- Cambodia and Sri Lanka

3.7 Supporting Organization’s Role & Responsibilities in GPP

• World Health Organization (WHO)

• International Pharmaceutical Federation (FIP)

• South East Asia Pharmaceutical (SEARPharm) Forum

o Work with local governments and National Pharmaceutical Associations in GPP

o Facilitate an implementation of pharmacy practice through projects at national level

o Measures for development and implementation of pharmacy accreditation

o Formulate policy statements on health issues of concern to pharmacists

o Monitor and update database yearly in Forum ExCo

o Seek cross border collaboration between Forums

• Western Pacific Pharmaceutical Forum (WPPF)

3.8 Support, Collaboration and Implementation Mechanism

• Changing perception of the role of pharmacists among themselves

• Improving the quality of pharmacy practice

3.1 General Information (in 2006 2005 2004 …....)

Community Pharmacy related

Ethics: Which organisation is responsible? …………………...………………………….………………………………

Disciplinary actions: Which organisation is responsible? …………………...…………………..………………………